The board of directors of Jenscare Scientific Co., Ltd. announced that the Group has submitted a pre-submission for the early feasibility study (EFS) of LuX-Valve Plus, which has been officially accepted by the Food and Drug Administration of the United States ("FDA"). The preparation of LuX- Valve Plus's Investigational Device Exemption (IDE) application in the United States has officially commenced. It marks the significant progress made by LuX-Valve Plus in the United States clinical trial registration process and in overseas business expansion.

The Group will continue to promote the global clinical and commercial activities of its transcatheter tricuspid valve replacement products, so as to benefit the huge market of tricuspid regurgitation patients. There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.